This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Glaser, K. B. Articles by Davidsen, S. K. Search for Related Content PubMed PubMed Citation Articles by Glaser, K. B. Articles by Davidsen, S. K.

Cancer Research and Advanced Technologies, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064

¹ To whom requests for reprints should be addressed, at Cancer Research, R47J-AP9, 100 Abbott Park Road, Abbott Park, IL 60064-6121. Phone: (847) 937-1558; Fax: (847) 935-3622; E-mail: keith.glaser{at}abbott.com

Acetylation of histones in chromatin is one mechanism involved in the regulation of gene transcription and is tightly controlled by the balance of acetyltransferase and deacetylase (HDAC) activities. In cancer, some genes are repressed by the inappropriate recruitment of HDACs, e.g., tumor suppressor genes. To understand the genomic effects of HDAC inhibition on gene transcription we studied the gene expression profiles of T24 bladder and MDA breast carcinoma cells treated with three HDAC inhibitors, suberoylanilide hydroxamic acid, trichostatin A, and MS-27-275. The gene expression profiles of the HDAC inhibitors were generally similar to one another and differed substantially from those produced by structurally related inactive analogues; consequently, the changes in gene expression are mechanism-based. Hierarchical clustering of expression profiles demonstrated a greater similarity between the two hydroxamate-containing inhibitors (suberoylanilide hydroxamic acid and trichostatin A) than with MS-27-275. This difference was also supported by cell phenotypic experiments. As many genes were down-regulated as up-regulated by HDAC inhibitor treatment. Comparison of the data sets defined a common ("core") set of 13 genes regulated by all of the HDAC inhibitors in three cell lines, 8 up-regulated and 5 down-regulated. Ten of 13 genes were confirmed in dose response studies in T24 cells by quantitative-PCR. The core regulated genes are involved predominantly in cell cycle/apoptosis and DNA synthesis in response to HDAC inhibitors. These data will aide in understanding the complex set of events in cells in response to chromatin remodeling induced by HDAC inhibition, which may be responsible for antitumor effects.

This article has been cited by other articles:

				A. M. Sargeant, R. C. Rengel, S. K. Kulp, R. D. Klein, S. K. Clinton, Y.-C. Wang, and C.-S. Chen OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., May 15, 2008; 68(10): 3999 - 4009. [Abstract] [Full Text] [PDF]

				C. A. Hassig, K. T. Symons, X. Guo, P.-M. Nguyen, T. Annable, P. L. Wash, J. E. Payne, D. A. Jenkins, C. Bonnefous, C. Trotter, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Ther., May 1, 2008; 7(5): 1054 - 1065. [Abstract] [Full Text] [PDF]

				I. Fenic, H. M. Hossain, V. Sonnack, S. Tchatalbachev, F. Thierer, J. Trapp, K. Failing, K. S. Edler, M. Bergmann, M. Jung, et al. In Vivo Application of Histone Deacetylase Inhibitor Trichostatin-A Impairs Murine Male Meiosis J Androl, March 1, 2008; 29(2): 172 - 185. [Abstract] [Full Text] [PDF]

				C. Yu, B. B. Friday, L. Yang, P. Atadja, D. Wigle, J. Sarkaria, and A. A. Adjei Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells Neuro-oncol, January 1, 2008; 10(3): 309 - 319. [Abstract] [Full Text] [PDF]

				K. K.W. To, O. Polgar, L. M. Huff, K. Morisaki, and S. E. Bates Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells Mol. Cancer Res., January 1, 2008; 6(1): 151 - 164. [Abstract] [Full Text] [PDF]

				L. Magnaghi-Jaulin, G. Eot-Houllier, G. Fulcrand, and C. Jaulin Histone Deacetylase Inhibitors Induce Premature Sister Chromatid Separation and Override the Mitotic Spindle Assembly Checkpoint Cancer Res., July 1, 2007; 67(13): 6360 - 6367. [Abstract] [Full Text] [PDF]

				S. Senese, K. Zaragoza, S. Minardi, I. Muradore, S. Ronzoni, A. Passafaro, L. Bernard, G. F. Draetta, M. Alcalay, C. Seiser, et al. Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation Mol. Cell. Biol., July 1, 2007; 27(13): 4784 - 4795. [Abstract] [Full Text] [PDF]

				S. S. Ramalingam, R. A. Parise, R. K. Ramananthan, T. F. Lagattuta, L. A. Musguire, R. G. Stoller, D. M. Potter, A. E. Argiris, J. A. Zwiebel, M. J. Egorin, et al. Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies Clin. Cancer Res., June 15, 2007; 13(12): 3605 - 3610. [Abstract] [Full Text] [PDF]

				L. R. Simard, M-C Belanger, S. Morissette, M. Wride, T. W. Prior, and K. J. Swoboda Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA Neurology, February 6, 2007; 68(6): 451 - 456. [Abstract] [Full Text] [PDF]

				J. L. Brogdon, Y. Xu, S. J. Szabo, S. An, F. Buxton, D. Cohen, and Q. Huang Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function Blood, February 1, 2007; 109(3): 1123 - 1130. [Abstract] [Full Text] [PDF]

				J. H. Schefe, M. Menk, J. Reinemund, K. Effertz, R. M. Hobbs, P. P. Pandolfi, P. Ruiz, T. Unger, and H. Funke-Kaiser A Novel Signal Transduction Cascade Involving Direct Physical Interaction of the Renin/Prorenin Receptor With the Transcription Factor Promyelocytic Zinc Finger Protein Circ. Res., December 8, 2006; 99(12): 1355 - 1366. [Abstract] [Full Text] [PDF]

				D. ZASKODOVA, M. REZACOVA, J. VAVROVA, D. VOKURKOVA, and A. TICHY Effect of Valproic Acid, a Histone Deacetylase Inhibitor, on Cell Death and Molecular Changes Caused by Low-Dose Irradiation Ann. N.Y. Acad. Sci., December 1, 2006; 1091(1): 385 - 398. [Abstract] [Full Text] [PDF]

				L. Geng, K. C. Cuneo, A. Fu, T. Tu, P. W. Atadja, and D. E. Hallahan Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of {gamma}-H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer Cancer Res., December 1, 2006; 66(23): 11298 - 11304. [Abstract] [Full Text] [PDF]

				J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J.-P. Brunet, A. Subramanian, K. N. Ross, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, September 29, 2006; 313(5795): 1929 - 1935. [Abstract] [Full Text] [PDF]

				Y. Zhang, M. Liao, and M. L. Dufau Phosphatidylinositol 3-Kinase/Protein Kinase C{zeta}-Induced Phosphorylation of Sp1 and p107 Repressor Release Have a Critical Role in Histone Deacetylase Inhibitor-Mediated Depression of Transcription of the Luteinizing Hormone Receptor Gene. Mol. Cell. Biol., September 1, 2006; 26(18): 6748 - 6761. [Abstract] [Full Text] [PDF]

				S. K. Kulp, C.-S. Chen, D.-S. Wang, C.-Y. Chen, and C.-S. Chen Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer Clin. Cancer Res., September 1, 2006; 12(17): 5199 - 5206. [Abstract] [Full Text] [PDF]

				T. J. Gaymes, R. A. Padua, M. Pla, S. Orr, N. Omidvar, C. Chomienne, G. J. Mufti, and F. V. Rassool Histone Deacetylase Inhibitors (HDI) Cause DNA Damage in Leukemia Cells: A Mechanism for Leukemia-Specific HDI-Dependent Apoptosis? Mol. Cancer Res., August 1, 2006; 4(8): 563 - 573. [Abstract] [Full Text] [PDF]

				C. Foglietti, G. Filocamo, E. Cundari, E. De Rinaldis, A. Lahm, R. Cortese, and C. Steinkuhler Dissecting the Biological Functions of Drosophila Histone Deacetylases by RNA Interference and Transcriptional Profiling J. Biol. Chem., June 30, 2006; 281(26): 17968 - 17976. [Abstract] [Full Text] [PDF]

				M. Sankaranarayanapillai, W. P. Tong, D. S. Maxwell, A. Pal, J. Pang, W. G. Bornmann, J. G. Gelovani, and S. M. Ronen Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy Mol. Cancer Ther., May 1, 2006; 5(5): 1325 - 1334. [Abstract] [Full Text] [PDF]

				F. Wischnewski, K. Pantel, and H. Schwarzenbach Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells Mol. Cancer Res., May 1, 2006; 4(5): 339 - 349. [Abstract] [Full Text] [PDF]

				K. Bhalla Overview and Cytoplasmic Targets of HDAC Inhibitors Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 309 - 312. [Full Text] [PDF]

				F. Liu, N. Pore, M. Kim, K. R. Voong, M. Dowling, A. Maity, and G. D. Kao Regulation of Histone Deacetylase 4 Expression by the SP Family of Transcription Factors Mol. Biol. Cell, February 1, 2006; 17(2): 585 - 597. [Abstract] [Full Text] [PDF]

				A. Matheu, P. Klatt, and M. Serrano Regulation of the INK4a/ARF Locus by Histone Deacetylase Inhibitors J. Biol. Chem., December 23, 2005; 280(51): 42433 - 42441. [Abstract] [Full Text] [PDF]

				W. Rocha, R. Sanchez, J. Deschenes, A. Auger, E. Hebert, J. H. White, and S. Mader Opposite Effects of Histone Deacetylase Inhibitors on Glucocorticoid and Estrogen Signaling in Human Endometrial Ishikawa Cells Mol. Pharmacol., December 1, 2005; 68(6): 1852 - 1862. [Abstract] [Full Text] [PDF]

				W.-S. Xu, G. Perez, L. Ngo, C.-Y. Gui, and P. A. Marks Induction of Polyploidy by Histone Deacetylase Inhibitor: A Pathway for Antitumor Effects Cancer Res., September 1, 2005; 65(17): 7832 - 7839. [Abstract] [Full Text] [PDF]

				S. Armeanu, M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al. Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate Cancer Res., July 15, 2005; 65(14): 6321 - 6329. [Abstract] [Full Text] [PDF]

				K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF]

				M. J. Peart, G. K. Smyth, R. K. van Laar, D. D. Bowtell, V. M. Richon, P. A. Marks, A. J. Holloway, and R. W. Johnstone Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors PNAS, March 8, 2005; 102(10): 3697 - 3702. [Abstract] [Full Text] [PDF]

				N. P. Mongan and L. J. Gudas Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR{beta}2 in breast cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 477 - 486. [Abstract] [Full Text] [PDF]

				B. GABRIELLI, R. WARRENER, A. BURGESS, and H. BEAMISH Defining the Chemotherapeutic Targets of Histone Deacetylase Inhibitors Ann. N.Y. Acad. Sci., December 1, 2004; 1030(1): 627 - 635. [Abstract] [Full Text] [PDF]

				X. Zhang, W. Wharton, Z. Yuan, S.-C. Tsai, N. Olashaw, and E. Seto Activation of the Growth-Differentiation Factor 11 Gene by the Histone Deacetylase (HDAC) Inhibitor Trichostatin A and Repression by HDAC3 Mol. Cell. Biol., June 15, 2004; 24(12): 5106 - 5118. [Abstract] [Full Text] [PDF]

				M. Adachi, Y. Zhang, X. Zhao, T. Minami, R. Kawamura, Y. Hinoda, and K. Imai Synergistic Effect of Histone Deacetylase Inhibitors FK228 and m-Carboxycinnamic Acid Bis-Hydroxamide with Proteasome Inhibitors PSI and PS-341 against Gastrointestinal Adenocarcinoma Cells Clin. Cancer Res., June 1, 2004; 10(11): 3853 - 3862. [Abstract] [Full Text] [PDF]

				X. D. Zhang, S. K. Gillespie, J. M. Borrow, and P. Hersey The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells Mol. Cancer Ther., April 1, 2004; 3(4): 425 - 435. [Abstract] [Full Text] [PDF]